- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05628961
Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics
May 22, 2023 updated by: SRI International
An Open-Label, First-In-Human Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics, and Excretion in Healthy Participants
The study objectives are to define the safety and tolerability profile of oral, single ascending dose (SAD) levels of HOPO 14-1 capsules in cohorts of healthy participants and to assess the pharmacokinetic (PK) and excretion profile of HOPO 14-1.
The study hypothesis is that a single dose of HOPO 14-1 will be safe and tolerable up to 7500 mg.
Study Overview
Detailed Description
The currently available therapy for radionuclide internal contamination is suboptimal.
Pharmacological and toxicological data support the clinical development of HOPO 14-1 for decorporation of radionuclides.
Study Type
Interventional
Enrollment (Anticipated)
42
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Medical Director
- Phone Number: 734-527-4200
- Email: clinical-trials@sri.com
Study Contact Backup
- Name: Director Clinical Operations
- Phone Number: 734-527-4200
- Email: clinical-trials@sri.com
Study Locations
-
-
Michigan
-
Plymouth, Michigan, United States, 48170
- Recruiting
- SRI Biosciences Clinical Trials Unit
-
Contact:
- Clinical Site Manager
- Phone Number: 734-527-4200
- Email: clinical-trials@sri.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Ability of participant to understand the requirements of the study, provide written informed consent, and agree to abide by the study requirements
- Agree to use contraception from time of screening until 14 days after dosing (Day 14) if female is of childbearing potential or male is with female partner of childbearing potential.
- In good general health based on medical history, physical examination (PE), and screening evaluations.
- Negative urine or blood screen for drugs of abuse (except if participant provides prescription justifying use prior to urine screen).
- Body weight ≥ 50 kilogram (kg) and ≤ 110 kg. If body weight is over 110 kg, then body mass index (BMI) will be considered and must be ≤ 40 kg/m^2.
Exclusion Criteria:
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol.
- Any hematology, chemistry, coagulation, or urinalysis value on screening labs defined in the United States Food and Drug Administration (FDA) Guidance for Industry Toxicity Grading Scale as Grade 1 or higher.
- Any clinically significant electrocardiogram (ECG) abnormality
- Pregnant or breastfeeding
- Active substance abuse or history of any medical or psychiatric condition that would jeopardize the participant's safety or the participant's ability to comply with the protocol.
- Received an organ transplant (solid or bone marrow).
- Received a blood transfusion within 3 months of dosing.
- Difficulty swallowing tablets or capsules.
- Febrile illness or significant infection within 7 days of dosing.
- Symptoms of hypotension (lightheadedness, syncope, balance disturbances, or extreme fatigue) within 48 hours of dosing.
- Hepatitis B virus surface antigen (HBsAg) positive or serologic (antibody positive) evidence of infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV).
- Tested positive for SARS-CoV-2 (COVID-19) within 21 days of dosing.
- Chelation therapy (e.g., ethylenediaminetetraacetic acid [EDTA], diethylenetriamine pentaacetate [DTPA]) in the past year.
- Use of laxatives, antibiotics, and/or antacids within 7 days of dosing.
- Use of investigational drugs within 60 days of dosing or 5 half-lives, whichever is longer.
- Received a vaccination within 30 days of dosing.
- Potential allergic reaction to product (oleic acid or HOPO 14-1 product).
- Past or current medical problems or findings from physical examination (PE) or laboratory testing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: 100 mg
Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
|
HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
|
Experimental: Cohort 2: 200 mg
Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
|
HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
|
Experimental: Cohort 3: 500 mg
Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
|
HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
|
Experimental: Cohort 4: 1200 mg
Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
|
HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
|
Experimental: Cohort 5: 2500 mg
Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
|
HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
|
Experimental: Cohort 6: 5000 mg
Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
|
HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
|
Experimental: Cohort 7: 7500 mg
Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
|
HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with One or More Adverse Events
Time Frame: Up to 14 days
|
Up to 14 days
|
Number of Participants with One or More Drug-Related Adverse Events
Time Frame: Up to 14 days
|
Up to 14 days
|
Number of Participants with One or More Adverse Events by Maximum Severity
Time Frame: Up to 14 days
|
Up to 14 days
|
Number of Participants with One or More Serious Adverse Events
Time Frame: Up to 14 days
|
Up to 14 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Observed Maximum Plasma Concentration (Cmax)
Time Frame: Up to Day 7
|
Up to Day 7
|
Observed Time to Reach Cmax (Tmax)
Time Frame: Up to Day 7
|
Up to Day 7
|
Area Under the Plasma Concentration Time Curve up to the Last Blood Collection Time with a Measurable Concentration (AUClast)
Time Frame: Up to Day 7
|
Up to Day 7
|
Extrapolated to Infinity (AUC0-inf)
Time Frame: Up to Day 7
|
Up to Day 7
|
Terminal Half-Life (t 1/2)
Time Frame: Up to Day 7
|
Up to Day 7
|
Apparent Volume of Distribution after Oral Administration (V/F)
Time Frame: Up to Day 7
|
Up to Day 7
|
Oral Systemic Clearance Rate (CL/F)
Time Frame: Up to Day 7
|
Up to Day 7
|
Cumulative Amount Excreted in Urine
Time Frame: Up to Day 7
|
Up to Day 7
|
Cumulative Amount Excreted in Feces
Time Frame: Up to Day 7
|
Up to Day 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Principal Investigator, SRI International
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 15, 2023
Primary Completion (Anticipated)
April 1, 2024
Study Completion (Anticipated)
April 1, 2024
Study Registration Dates
First Submitted
November 17, 2022
First Submitted That Met QC Criteria
November 17, 2022
First Posted (Actual)
November 29, 2022
Study Record Updates
Last Update Posted (Actual)
May 24, 2023
Last Update Submitted That Met QC Criteria
May 22, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- SRI-HOPO-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Toxicity;Chemical
-
Assiut UniversityUnknown
-
Baxalta now part of ShireDynPort Vaccine Company LLC, A GDIT CompanyCompletedHealthy Volunteers | Chemical Terrorism | Chemical WarfareUnited States
-
Sun Yat-sen UniversityCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
HealthpointWithdrawn
-
Assaf-Harofeh Medical CenterUnknown
-
Assistance Publique - Hôpitaux de ParisMission Interministérielle de Lutte contre les Drogues et les Conduites Addictives...Not yet recruitingCHEMICAL SUBMISSION
-
Assiut UniversityNot yet recruitingLiver Toxicity, Chemically-Induced
-
University Hospital, Gentofte, CopenhagenCompletedMultiple Chemical SensitivitiesDenmark
Clinical Trials on HOPO 14-1
-
PfizerCompleted
-
Boehringer IngelheimCompleted
-
Chang Gung Memorial HospitalCompletedHuman Papillomavirus | Vaginal InfectionTaiwan
-
Laboratorios Leti, S.L.CompletedAsthma | Rhinitis | RhinoconjunctivitisSpain
-
Cengiz Gokcek Women's and Children's HospitalUnknownPreterm Premature Rupture of MembranesTurkey
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Alexandria UniversityUnknownDiagnoses, Syndromes, and Conditions | Sepsis Following A Procedure
-
Northwestern UniversityCompleted
-
Newbridge HouseCompletedBody Image | Exposure